Co-Authors
This is a "connection" page, showing publications co-authored by DAVID SANGHYUN HONG and JAMES WELSH.
Connection Strength
2.834
-
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909.
Score: 0.734
-
Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report. Melanoma Res. 2023 08 01; 33(4):332-337.
Score: 0.236
-
Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease. Radiother Oncol. 2023 06; 183:109618.
Score: 0.232
-
Inhibition of the CD47-SIRPa axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data. Front Immunol. 2022; 13:1027235.
Score: 0.226
-
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol. 2021 09; 162:60-67.
Score: 0.206
-
Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020 10; 8(2).
Score: 0.196
-
Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J Immunother Cancer. 2019 09 04; 7(1):237.
Score: 0.182
-
Phase I Trial: SABR and Ipilimumab-Response. Clin Cancer Res. 2017 01 01; 23(1):321.
Score: 0.151
-
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396.
Score: 0.148
-
Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014 Sep; 2(9):831-8.
Score: 0.128
-
Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014 Aug 01; 89(5):1084-1091.
Score: 0.127
-
Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. Elife. 2021 11 09; 10.
Score: 0.053
-
A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden. Nat Biomed Eng. 2021 04; 5(4):297-308.
Score: 0.050
-
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. J Immunother Cancer. 2020 10; 8(2).
Score: 0.049
-
Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy. Sci Adv. 2020 05; 6(18):eaay6298.
Score: 0.047
-
Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Sci Rep. 2018 01 31; 8(1):1922.
Score: 0.041
-
Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013 Feb; 8(2):238-45.
Score: 0.029